BIOTConsumer Defensive · Household & Personal Products

BIOT Stock Forecast: Instinct Bio Technical Co. Holdings, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026

$0.44

−7.38% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 1 Aug 2026 — in the lower half.

Market cap

$12.5M

Ticker Nerd rank

33 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−84.1%

From high

−97.2%

From low

0.0%

$16

Range since 24 July 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

BIOT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Instinct Bio Technical Co. Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Accruals

Value

Issuance

Quality

Revisions

Momentum

Growth

Size (99): Smaller than most of the companies we track.

Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.

The rank is the raw material. Whether the rules would actually own Instinct Bio Technical Co. Holdings, Inc. — and when they’d sell — is the membership.

Wall Street

BIOT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIOT, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

BIOT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Instinct Bio Technical Co. Holdings, Inc. (BIOT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −10.9×
Price / sales: 4.5×
Price / book: 5.6×
EV / EBITDA: 33.4×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 4.7%
Net margin: 72.4%

Returns & dividend

Return on equity: 3.2%
Return on assets: 2.4%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BIOT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products

Company	Market cap	TKN rank
BIOTInstinct Bio Technical Co. Holdings, Inc.	$12.5M	33
BYAHPark Ha Biological Technology Co. Ltd.	$2.3M	20
TANHTantech Holdings Ltd.	$6.0M	17
RAYRaytech Holding Ltd.	$16.2M	8
DSYBig Tree Cloud Holdings Ltd.	$31.1M	4
UGUnited-Guardian, Inc.	$32.4M	78
GROVGrove Collaborative Holdings, Inc.	$46.2M	97

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIOT appears on the weeks it earns a place.

News

Latest BIOT news & analysis

BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia's Fastest-Growing Aesthetics Markets

GlobeNewsWire · 29 July 2026positive

BIOT announced it will launch Indonesia's first subscription-model beauty clinics under its own Japanese brand "GENRÊVER CLINIC," aiming to create a recurring-revenue platform in the aesthetics market.

Why it matters — The move represents a strategic push into recurring-revenue streams in a fast-growing Asian market, which could diversify BIOT's business model beyond one-time service sales.

FAQ

Frequently asked questions about BIOT stock

How does Ticker Nerd's model rank BIOT?

As at 1 Aug 2026, Instinct Bio Technical Co. Holdings, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the BIOT stock forecast for 2030?

No analyst covering Instinct Bio Technical Co. Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIOT are extrapolating price history, which says nothing about the business.

What does Instinct Bio Technical Co. Holdings, Inc. do?

Instinct Bio Technical Company Holdings Inc. focuses on stem cell and regenerative medicine-related products, wellness, and beauty encompassing from research and development, manufacturing, branding, and distribution.

What is the latest news on BIOT?

The most recent item we track (GlobeNewsWire, 29 July 2026): "BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia's Fastest-Growing Aesthetics Markets". BIOT announced it will launch Indonesia's first subscription-model beauty clinics under its own Japanese brand "GENRÊVER CLINIC," aiming to create a recurring-revenue platform in the aesthetics market.

Company

About Instinct Bio Technical Co. Holdings, Inc.

CEO Mr. Tomoki Nagano · Japan · https://instinct-biot.com